help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Costagliola, S.
Right arrow Articles by Carayon, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Costagliola, S.
Right arrow Articles by Carayon, P.

Endocrinology, Vol 128, 1555-1562, Copyright © 1991 by Endocrine Society

ARTICLES

Monoclonal antiidiotypic antibodies interact with the 93 kilodalton thyrotropin receptor and exhibit heterogeneous biological activities

S Costagliola, J Ruf, MJ Durand-Gorde and P Carayon
U38 INSERM, Marseille, France.

Ten antiidiotypic monoclonal antibodies (AI mAb) reacting with the TSH receptor were produced by immunization of mice with a mouse mAb directed to a TSH epitope involved in the binding of the hormone to the receptor. The AI mAb were tested for their effects on the TSH receptor- adenylate cyclase system. Four AI mAb behave as agonists of TSH as they compete with TSH for binding to the receptor and stimulate the adenylate cyclase activity. Five AI mAb inhibited both TSH binding to the receptor and adenylate cyclase activity in the presence and absence of TSH; they were thus considered as antagonists of the hormone. One mAb inhibited only slightly the binding of TSH to the receptor and did not interfere significantly with the adenylate cyclase activity. The 10 AI mAb bound with various apparent affinities to solubilized thyroid membrane proteins but not to kidney, spleen, and liver membranes. Membrane desialylation did not significantly alter the binding of the AI mAb whereas deglycosylation modified more or less strongly the binding of mAb to thyroid membranes. It was also shown that the binding to solubilized thyroid membranes of the 10 mAb was inhibited by anti- TSH receptor autoantibodies present in patients with autoimmune disease. The mAb were further analyzed by Western blot analysis. One mAb did not react with the antigen, which suggested that it was directed to a conformational epitope. The other 9 mAb reacted with a protein of 70 kilodaltons and 5 revealed another band of 93 kilodaltons in accordance with the TSH receptor size deduced from the recently molecular cloning.


This article has been cited by other articles:


Home page
 EndocrinologyHome page
P. Crisanti, B. Omri, E. J. Hughes, G. Meduri, C. Hery, E. Clauser, C. Jacquemin, and B. Saunier
The Expression of Thyrotropin Receptor in the Brain
Endocrinology, February 1, 2001; 142(2): 812 - 822.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
B. Rapoport, G. D. Chazenbalk, J. C. Jaume, and S. M. McLachlan
The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies
Endocr. Rev., December 1, 1998; 19(6): 673 - 716.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1991 by The Endocrine Society